Charles Schwab Investment Management Inc Anavex Life Sciences Corp. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 709,616 shares of AVXL stock, worth $7.65 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
709,616
Previous 669,911
5.93%
Holding current value
$7.65 Million
Previous $5.75 Million
13.83%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding AVXL
# of Institutions
195Shares Held
32MCall Options Held
1.33MPut Options Held
875K-
Black Rock Inc. New York, NY6.39MShares$68.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$55.1 Million0.0% of portfolio
-
State Street Corp Boston, MA2.95MShares$31.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$21.8 Million0.0% of portfolio
-
Nwam LLC Mercer Island, WA1.02MShares$11 Million0.83% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $840M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...